News Search Results
Nov 10, 2025, 09:06 ET B. Riley Securities Strengthens Healthcare and Life Sciences Investment Banking with Senior Hire
in biopharma and life sciences, including specialty pharmaceuticals, CROs, CDMOs, tools and diagnostics – and strong relationships with leading biotechnology companies and investors. Over his career, he has advised on more than 140 transactions with combined deal value exceeding $30 billion.
More news about: B. Riley Securities
Nov 10, 2025, 09:04 ET FDA Completes Safety for Gallant's First Ready-to-Use Stem Cell Therapy for Refractory FCGS
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced a significant advancement in the FDA's conditional approval process for
More news about: Gallant
Nov 10, 2025, 08:38 ET The DNA Company Named Functional Genomics Innovation of the Year for the 2025 BioTech Breakthrough Awards
that support their well-being." The BioTech Breakthrough Awards honor excellence and innovation in the life sciences and biotechnology industries, recognizing companies, products, and research that are driving meaningful progress in health and medical technology. This year's program
More news about: The DNA Company
Nov 10, 2025, 08:30 ET Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced 24-week post end of treatment
More news about: Brii Biosciences Limited
Nov 10, 2025, 08:30 ET 騰盛博藥在2025年AASLD大會上發佈ENSURE II期研究最新突破性數據，進一步強調BRII-179作為慢乙肝治癒性療法的潛力
Elebsiran是一種經皮下注射給藥的靶向乙型肝炎病毒（HBV）的小干擾核糖核酸（siRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。2024年5月，中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）授予elebsiran突破性療法認定。 關於騰盛博藥
More news about: 騰盛博藥生物科技有限公司
Nov 10, 2025, 08:30 ET Rebuilding the Tumor Microenvironment for In Vitro Discovery, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
About Halia Therapeutics Halia Therapeutics is an innovative biotechnology company focused on developing first-in-class inflammasome inhibitors for inflammatory diseases and hematologic malignancies. The company is committed
More news about: Halia Therapeutics
Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
About Halia Therapeutics Halia Therapeutics is an innovative biotechnology company focused on developing first-in-class inflammasome inhibitors for inflammatory diseases and hematologic malignancies. The company is committed
More news about: Halia Therapeutics
Nov 10, 2025, 08:00 ET Alpha-9 Oncology Appoints Paul Blanchfield as Chief Executive Officer
and a member of the Board of Directors. Mr. Blanchfield brings more than 15 years of diverse leadership experience across radiopharmaceuticals, biotechnology, and healthcare - most recently as President of Lantheus, where he oversaw Commercial, R&D, Medical, and Technical Operations.
More news about: Alpha-9 Oncology, Inc.
Nov 10, 2025, 07:00 ET Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Nov 10, 2025, 07:00 ET Origin Agritech Strengthens Gene Editing Platform through Patent License Agreement with Shunfeng BioTech
"Origin"), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. ("Shunfeng BioTech") for the Cas-SF01 gene editing tool. This collaboration grants Origin long-term access to fully IP-protected gene
More news about: Origin Agritech Limited
Nov 10, 2025, 06:00 ET Muna Therapeutics Announces First Subjects Dosed in Phase 1 Trial of Novel Oral TREM2 Agonist for Early Alzheimer's Disease
COPENHAGEN, Denmark, Nov. 10, 2025 /PRNewswire/ -- Muna Therapeutics, a clinical stage biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, today announced that the first subjects have been dosed in
More news about: Muna Therapeutics
Nov 10, 2025, 03:30 ET Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
LONDON, Nov. 10, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, today provided an update
More news about: Leucid Bio
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
cardiovascular and metabolic, ophthalmology and other major diseases, jointly announced with Sanegene Bio USA Inc. (SanegeneBio), a global clinical-stage biotechnology company focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, that the preliminary results from
More news about: Innovent Biologics
Nov 08, 2025, 17:45 ET New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Nov 08, 2025, 12:24 ET Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
strategically important step in Zinzino's growth plans, with a focus on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Sanki is a direct sales company in the health segment,
More news about: Zinzino
Nov 08, 2025, 10:55 ET Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase distribution capacity in North America and South America
strategically important step in Zinzino's growth plans, with a focus on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Sanki is a direct sales company in the health segment,
More news about: Zinzino
Nov 08, 2025, 10:15 ET AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Nov 08, 2025, 08:30 ET AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that 48-week data from its two ongoing Phase II studies of AHB-137 were presented in a late-breaking poster session
More news about: AusperBio Therapeutics Inc.
Nov 08, 2025, 05:00 ET SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("Lilly").
More news about: SanegeneBio
Nov 07, 2025, 23:59 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Monday, December 15, 2025. CASE ALLEGATIONS: MoonLake is a clinical stage biotechnology company that focuses on developing therapies for inflammatory skin and joint diseases. According to the complaint, MoonLake's sole drug candidate
More news about: Robbins Geller Rudman & Dowd LLP
Nov 07, 2025, 17:55 ET Class Action Reminder: AVTR Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Avantor, Inc. Class Action Lawsuit
Company: Avantor, Inc. (NYSE: AVTR) provides scientific products and services for customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries. Class Period: March
More news about: Robbins LLP
Nov 07, 2025, 16:05 ET Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PALO ALTO, Calif., Nov. 7, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the closing of its initial public
More news about: Evommune, Inc
Nov 07, 2025, 10:03 ET Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
The BioTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global life sciences and biotechnology industries. Conducted annually by BioTech Breakthrough, a leading independent market intelligence organization, the awards celebrate excellence
More news about: Klotho Neurosciences, Inc.
Nov 07, 2025, 09:29 ET Aquaporin A/S: Notice to convene an extraordinary general meeting
Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, hereby convenes an extraordinary general meeting of Aquaporin to be held on: Monday, December 1, 2025,
More news about: Aquaporin A/S